NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

10374	Companies
216189	Keywords
145888	Articles
114464	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 09/26/2024 at 12:30, 1 year 7 months ago

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs
NanoViricides, Inc. obtains right of first refusal for antiviral drug developments from TheraCour Pharma, expands drug portfolio with new MOU and revolutionary nanoviricide technology, including NV-387 for multiple viral infections

NV-387 Antiviral Drugs NanoViricides Inc. TheraCour Pharma Nanoviricide Technology
BRIEF

published on 08/26/2024 at 13:35, 1 year 8 months ago

NanoViricides Investigates NV-387 for MPOX Treatment Under WHO's MEURI Protocol

NanoViricides NV-387 Mpox WHO MEURI Protocol
BRIEF

published on 08/26/2024 at 13:35, 1 year 8 months ago

NanoViricides étudie le NV-387 pour le traitement du MPOX dans le cadre du protocole MEURI de l'OMS

NanoViricides NV-387 Mpox Protocole MEURI OMS
PRESS RELEASE

published on 08/26/2024 at 13:30, 1 year 8 months ago

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX
NanoViricides, Inc. reports investigating NV-387 for MPOX treatment under WHO MEURI protocol amidst 2024 outbreak. NV-387 shows promise in animal studies for broad-spectrum antiviral use

NanoViricides NV-387 Broad-spectrum Antiviral MPOX Treatment WHO MEURI Protocol
BRIEF

published on 08/19/2024 at 12:35, 1 year 8 months ago

NanoViricides Advances Towards Phase II Trial of NV-387

NanoViricides NV-387 Antiviral Therapy Phase II Trial RSV, COVID, Influenza
BRIEF

published on 08/19/2024 at 12:35, 1 year 8 months ago

NanoViricides avance vers la phase II de l'essai du NV-387

NanoViricides NV-387 Essai De Phase II Thérapie Antivirale VRS, COVID, Grippe
PRESS RELEASE

published on 08/19/2024 at 12:30, 1 year 8 months ago

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
NanoViricides, Inc. provides update on Phase II clinical trial plans for broad-spectrum antiviral drug candidate NV-387 against RSV, COVID, and Influenza. Potential $12 Billion market. Novel trial design expected

NanoViricides NV-387 Clinical Trial Antiviral Phase II
BRIEF

published on 08/08/2024 at 12:35, 1 year 9 months ago

NanoViricides Updates Clinical Program and Strategy

NV-387 Clinical Trials RSV Treatment Antiviral Nanomedicines Broad-spectrum Antiviral
BRIEF

published on 08/08/2024 at 12:35, 1 year 9 months ago

NanoViricides met à jour son programme clinique et sa stratégie

NV-387 Essais Cliniques Antiviral À Large Spectre Nanomédicaments Antiviraux Traitement Du VRS
PRESS RELEASE

published on 08/08/2024 at 12:30, 1 year 9 months ago

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics
NanoViricides provides update on clinical program & strategy for novel antiviral drug NV-387, targeting Influenza, COVID, RSV & more. Broad-spectrum potential discussed

NanoViricides NV-387 Clinical Program Antiviral Drug Broad-spectrum

Accesswire

Published on 05/09/2026 at 01:55, 2 days 1 hour ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 2 days 1 hour ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 2 days 1 hour ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 2 days 3 hours ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 2 days 4 hours ago

Water Ways Announces Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 05/10/2026 at 16:05, 11 hours 13 minutes ago

RingConn Gen 3 Smart Ring Opens for Pre-Order: Bringing Vascular Insights to Effortless Everyday Wear
Published on 05/10/2026 at 14:00, 13 hours 18 minutes ago

MBC GROUP DELIVERS RESILIENT 1Q 2026 PERFORMANCE ANCHORED BY STRONG MBC SHAHID GROWTH
Published on 05/10/2026 at 11:45, 15 hours 33 minutes ago

Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Published on 05/09/2026 at 19:05, 1 day 8 hours ago

LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 2 days 6 hours ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations

Les Echos

Published on 05/07/2026 at 19:15, 3 days 8 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 3 days 8 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 3 days 8 hours ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 3 days 8 hours ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 3 days 8 hours ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE